---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062045"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:45:46.315389+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024

## Summary
- Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.
- Cash, cash equivalents and investments at $172.9M as of Sept 30, down from $245.2M at Dec 31, 2022; operating cash burn $74.5M YTD.
- Phase 2/3 LIFT-AD trial enrollment for fosgonimeton expected complete by Q1 2024; topline data anticipated in H2 2024.
- ATH-1105 (oral ALS candidate) IND-enabling studies ongoing; first-in-human study expected in H1 2024.
- New preclinical fosgonimeton data to be presented at Neuroscience 2023 (Nov 11-15) in Washington, D.C.

## SEC filing metadata
- accession: 0000950170-23-062045
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/0000950170-23-062045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/atha-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062045
- JSON: https://secwatch.observer/filing/0000950170-23-062045.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062045.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/0000950170-23-062045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.